+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs for HAE Market - Global Forecast 2026-2032- Product Image
Drugs for HAE Market - Global Forecast 2026-2032- Product Image
Sale

Drugs for HAE Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6117152
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Drugs for HAE Market is projected to reach USD 4.29 Billion in 2026. It is expected to continue growing at a CAGR of 12.24%, reaching USD 8.42 Billion by 2032.

Drugs for HAE: Executive Summary and Strategic Context

Hereditary angioedema (HAE) is a rare, potentially life-threatening disorder characterized by recurrent episodes of swelling caused by dysregulation of the bradykinin pathway. Drug therapy addresses acute attacks, short-term prevention around procedures, and long-term prophylaxis. Clinical decision-making is shaped by attack frequency, severity, age, administration route, treatment access, patient preference, and the need to minimize emergency intervention. The market is therefore defined by therapeutic differentiation as well as by diagnosis, continuity of care, and patient education.

Treatment Is Shifting Toward Prevention, Personalization, and Easier Administration

The HAE treatment landscape is moving from reliance on emergency rescue toward individualized prevention strategies that reduce attack burden and disruption to daily life. Treatment selection increasingly considers sustained control, tolerability, dosing frequency, self-administration, and suitability across age groups. Advances in diagnostic awareness are also important because delayed or incorrect diagnosis can expose patients to avoidable morbidity and inappropriate treatment. In parallel, care models are becoming more coordinated, linking specialist assessment, emergency planning, home treatment, and patient support.

Artificial Intelligence Can Strengthen Diagnosis, Adherence, and Evidence Generation

Artificial intelligence may support HAE care by identifying patterns in longitudinal clinical records, flagging patients with unexplained recurrent swelling, and helping clinicians distinguish bradykinin-mediated episodes from other forms of angioedema. Predictive tools could assist with attack-risk assessment, treatment adherence monitoring, and selection of follow-up intensity, provided they are validated in diverse populations. AI can also improve pharmacovigilance and real-world evidence generation by structuring patient-reported outcomes and treatment-response data. Its use requires strong privacy safeguards, transparent validation, clinician oversight, and careful management of false-positive and false-negative results.

Regional Dynamics Reflect Differences in Diagnosis, Specialist Access, and Reimbursement

North America benefits from established specialist networks, home-treatment capabilities, and comparatively broad awareness, while access and affordability remain important considerations. Europe combines strong rare-disease infrastructure with variation in reimbursement, prescribing pathways, and national treatment guidance. Asia-Pacific presents substantial opportunities to improve recognition, specialist capacity, and availability of modern therapies across highly diverse health systems. Latin America continues to require stronger diagnostic pathways, reliable access to therapies, and continuity between urban referral centers and underserved areas. In the Middle East, specialist concentration and uneven reimbursement influence treatment access, with regional centers playing a key role. Africa faces pronounced challenges in disease recognition, laboratory capacity, supply reliability, and access to specialist care, making education and referral infrastructure central priorities.

Economic and Security Groupings Reveal Uneven Health-System Readiness

ASEAN markets differ substantially in regulatory maturity, specialist availability, and public coverage, creating a need for adaptable access and education strategies. BRICS countries encompass large patient populations and varied capabilities, with opportunities to strengthen diagnosis, local expertise, and supply resilience. The European Union supports cross-border rare-disease collaboration, although national reimbursement and implementation remain differentiated. G7 health systems generally have stronger specialist infrastructure and evidence-generation capacity, while still confronting affordability and equitable access. GCC countries can leverage centralized healthcare planning and specialist hubs, but coverage and referral pathways vary. NATO members span diverse health systems; coordinated preparedness, procurement resilience, and clinical education can support continuity of care during disruptions.

Country-Level Priorities Range from Access Expansion to Diagnostic Capacity

Australia can build on specialist services and telehealth to improve reach across geographically dispersed communities. Brazil requires stronger referral networks, diagnostic awareness, and dependable access beyond major centers. Canada must address geographic dispersion and coordination between specialist and community care. China can advance diagnosis and specialist capacity across a large and varied healthcare system. France, Germany, Italy, and Spain have established clinical expertise but continue to navigate reimbursement, regional implementation, and equitable access. India needs expanded recognition, specialist training, and affordable treatment pathways. Japan and South Korea can use advanced healthcare infrastructure to improve early diagnosis, patient monitoring, and integrated care. Mexico would benefit from broader specialist coverage and more consistent access across public and private settings. Russia faces challenges associated with geographic scale, continuity of supply, and specialist distribution. The United Kingdom can further integrate rare-disease services, patient support, and national treatment pathways. The United States has extensive specialist and treatment capabilities, while affordability, insurance variation, and care coordination remain central issues.

Industry Leaders Should Prioritize Patient Outcomes, Access, and System Resilience

Leaders should differentiate therapies through clinically meaningful outcomes such as attack prevention, rapid control, usability, and quality-of-life improvement rather than relying solely on pharmacologic novelty. They should support evidence-based diagnosis through clinician education, referral tools, and collaboration with patient organizations. Access strategies should account for reimbursement variation, route of administration, healthcare-resource constraints, and the needs of underserved populations. Supply-chain planning should include resilient sourcing and contingency measures for essential therapies. Patient services can improve training, adherence, emergency preparedness, and collection of validated outcomes. Any AI deployment should be clinically governed, privacy-preserving, and evaluated for performance across demographic and geographic groups.

Methodology Combines Clinical, Policy, Geographic, and Patient-Care Analysis

This executive summary applies a structured qualitative review of the HAE treatment landscape. The analysis considers disease biology, acute and preventive treatment use, administration preferences, diagnostic pathways, specialist capacity, reimbursement conditions, regulatory environments, and healthcare-system readiness. Regional, group, and country perspectives are integrated to identify recurring access and implementation themes rather than to produce numerical market estimates. Interpretation should be validated against current clinical guidelines, regulatory decisions, health technology assessments, peer-reviewed evidence, and locally relevant patient and provider data.

HAE Care Is Advancing, but Access and Diagnosis Remain Strategic Priorities

The drugs-for-HAE landscape is being reshaped by a stronger emphasis on prevention, patient autonomy, sustained disease control, and evidence-based personalization. Therapeutic progress will deliver the greatest benefit when paired with earlier diagnosis, coordinated specialist care, reliable access, and practical patient support. Regional and country differences make locally adapted implementation essential. Industry leaders that combine clinical value with affordability, resilience, responsible data use, and measurable patient outcomes will be best positioned to support better HAE care.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Drugs for HAE Market, by Indication Type
7.1. Introduction
7.2. Acute Treatment
7.2.1. Bradykinin Receptor Antagonists
7.2.2. C1 Inhibitors
7.2.3. C1 Inhibitors
7.2.3.1. Plasma Derived
7.2.3.2. Recombinant
7.2.4. Kallikrein Inhibitors
7.2.4.1. Monoclonal
7.2.4.2. Small Molecule
7.3. Long Term Prophylaxis
7.3.1. C1 Inhibitors
7.3.1.1. Plasma Derived
7.3.1.2. Recombinant
7.3.2. Kallikrein Inhibitors
7.3.2.1. Monoclonal
7.3.2.2. Small Molecule
8. Drugs for HAE Market, by Drug Class
8.1. Introduction
8.2. Bradykinin Receptor Antagonists
8.3. C1 Inhibitors
8.3.1. Plasma Derived
8.3.2. Recombinant
8.4. Kallikrein Inhibitors
8.4.1. Monoclonal
8.4.2. Small Molecule
9. Drugs for HAE Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Drugs for HAE Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Retail Pharmacy
10.4. Specialty Pharmacy
11. Drugs for HAE Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.3. Pediatric
12. Drugs for HAE Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Drugs for HAE Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Drugs for HAE Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. ADARx Pharmaceuticals, Inc.
16.2. Arrowhead Pharmaceuticals, Inc.
16.3. Astria Therapeutics, Inc.
16.4. Attune Pharmaceuticals, Inc.
16.5. BioCryst Pharmaceuticals, Inc.
16.6. BioMarin Pharmaceutical Inc.
16.7. CSL Behring LLC
16.8. Grifols, S.A.
16.9. Intellia Therapeutics, Inc.
16.10. Ionis Pharmaceuticals, Inc.
16.11. KalVista Pharmaceuticals, Inc.
16.12. Pharming Group N.V.
16.13. Pharvaris N.V.
16.14. Regeneron Pharmaceuticals, Inc.
16.15. Sanofi S.A.
16.16. Swedish Orphan Biovitrum AB
16.17. Takeda Pharmaceutical Company Limited
16.18. Teva Pharmaceuticals Industries Ltd.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Drugs for HAE Market, Years Considered for the Study
FIGURE 2. Global Drugs for HAE Market, Research Design
FIGURE 3. Global Drugs for HAE Market, Research Framework
FIGURE 4. Global Drugs for HAE Market, Data Triangulation
FIGURE 5. Global Drugs for HAE Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Drugs for HAE Market Size, by Indication Type, 2025 vs 2032 (%)
FIGURE 7. Global Drugs for HAE Market Size, by Indication Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Drugs for HAE Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 9. Global Drugs for HAE Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Drugs for HAE Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Drugs for HAE Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Drugs for HAE Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Drugs for HAE Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Drugs for HAE Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 15. Global Drugs for HAE Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Drugs for HAE Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Drugs for HAE Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Drugs for HAE Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Drugs for HAE Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Drugs for HAE Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Drugs for HAE Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Drugs for HAE Market Segmentation & Coverage
TABLE 2. Global Drugs for HAE Market Size, 2017-2032 (USD Million)
TABLE 3. Global Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 4. Global Acute Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Acute Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Acute Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Bradykinin Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Bradykinin Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Bradykinin Receptor Antagonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global C1 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global C1 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global C1 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global C1 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global C1 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global C1 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Plasma Derived Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Plasma Derived Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Plasma Derived Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Kallikrein Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Kallikrein Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Kallikrein Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Monoclonal Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Monoclonal Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Monoclonal Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Small Molecule Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Small Molecule Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Small Molecule Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Long Term Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Long Term Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Long Term Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global C1 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global C1 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global C1 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Plasma Derived Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Plasma Derived Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Plasma Derived Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Kallikrein Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Kallikrein Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Kallikrein Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Monoclonal Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Monoclonal Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Monoclonal Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Small Molecule Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Small Molecule Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Small Molecule Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 53. Global Bradykinin Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Bradykinin Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Bradykinin Receptor Antagonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global C1 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global C1 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global C1 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Plasma Derived Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Plasma Derived Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Plasma Derived Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Kallikrein Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Kallikrein Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Kallikrein Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Monoclonal Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Monoclonal Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Monoclonal Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Small Molecule Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Small Molecule Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Small Molecule Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 75. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 85. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 95. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Drugs for HAE Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Asia-Pacific Drugs for HAE Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 114. Asia-Pacific Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 115. Asia-Pacific Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 116. North America Drugs for HAE Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. North America Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 118. North America Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 119. North America Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 120. North America Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 121. North America Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 122. North America Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 123. North America Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 124. North America Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 125. North America Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 126. North America Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 127. North America Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 128. North America Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. North America Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 130. Latin America Drugs for HAE Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Latin America Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 132. Latin America Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 133. Latin America Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 134. Latin America Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 135. Latin America Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 136. Latin America Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 137. Latin America Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 138. Latin America Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 139. Latin America Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 140. Latin America Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 141. Latin America Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 142. Latin America Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 143. Latin America Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 144. Europe Drugs for HAE Market Size, by Region, 2017-2032 (USD Million)
TABLE 145. Europe Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 146. Europe Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 147. Europe Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 148. Europe Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 149. Europe Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 150. Europe Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 151. Europe Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 152. Europe Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 153. Europe Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 154. Europe Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 155. Europe Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 156. Europe Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 157. Europe Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 158. Middle East Drugs for HAE Market Size, by Region, 2017-2032 (USD Million)
TABLE 159. Middle East Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 160. Middle East Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 161. Middle East Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 162. Middle East Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 163. Middle East Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 164. Middle East Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 165. Middle East Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 166. Middle East Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 167. Middle East Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 168. Middle East Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 169. Middle East Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 170. Middle East Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 171. Middle East Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 172. Africa Drugs for HAE Market Size, by Region, 2017-2032 (USD Million)
TABLE 173. Africa Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 174. Africa Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 175. Africa Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 176. Africa Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 177. Africa Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 178. Africa Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 179. Africa Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 180. Africa Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 181. Africa Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 182. Africa Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 183. Africa Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 184. Africa Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 185. Africa Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 186. Global Drugs for HAE Market Size, by Group, 2017-2032 (USD Million)
TABLE 187. ASEAN Drugs for HAE Market Size, by Group, 2017-2032 (USD Million)
TABLE 188. ASEAN Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 189. ASEAN Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 190. ASEAN Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 191. ASEAN Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 192. ASEAN Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 193. ASEAN Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 194. ASEAN Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 195. ASEAN Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 196. ASEAN Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 197. ASEAN Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 198. ASEAN Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 199. ASEAN Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 200. ASEAN Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 201. GCC Drugs for HAE Market Size, by Group, 2017-2032 (USD Million)
TABLE 202. GCC Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 203. GCC Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 204. GCC Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 205. GCC Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 206. GCC Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 207. GCC Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 208. GCC Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 209. GCC Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 210. GCC Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 211. GCC Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 212. GCC Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 213. GCC Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. GCC Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 215. European Union Drugs for HAE Market Size, by Group, 2017-2032 (USD Million)
TABLE 216. European Union Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 217. European Union Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 218. European Union Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 219. European Union Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 220. European Union Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 221. European Union Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 222. European Union Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 223. European Union Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 224. European Union Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 225. European Union Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 226. European Union Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 227. European Union Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 228. European Union Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 229. BRICS Drugs for HAE Market Size, by Group, 2017-2032 (USD Million)
TABLE 230. BRICS Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 231. BRICS Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 232. BRICS Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 233. BRICS Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 234. BRICS Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 235. BRICS Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 236. BRICS Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 237. BRICS Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 238. BRICS Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 239. BRICS Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 240. BRICS Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 241. BRICS Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 242. BRICS Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 243. G7 Drugs for HAE Market Size, by Group, 2017-2032 (USD Million)
TABLE 244. G7 Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 245. G7 Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 246. G7 Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 247. G7 Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 248. G7 Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 249. G7 Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 250. G7 Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 251. G7 Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 252. G7 Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 253. G7 Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 254. G7 Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 255. G7 Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 256. G7 Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 257. NATO Drugs for HAE Market Size, by Group, 2017-2032 (USD Million)
TABLE 258. NATO Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 259. NATO Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 260. NATO Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 261. NATO Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 262. NATO Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 263. NATO Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 264. NATO Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 265. NATO Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 266. NATO Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 267. NATO Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 268. NATO Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 269. NATO Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 270. NATO Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 271. Global Drugs for HAE Market Size, by Country, 2017-2032 (USD Million)
TABLE 272. United States Drugs for HAE Market Size, 2017-2032 (USD Million)
TABLE 273. United States Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 274. United States Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 275. United States Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 276. United States Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 277. United States Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 278. United States Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 279. United States Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 280. United States Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 281. United States Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 282. United States Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 283. United States Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 284. United States Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 285. United States Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 286. Canada Drugs for HAE Market Size, 2017-2032 (USD Million)
TABLE 287. Canada Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 288. Canada Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 289. Canada Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 290. Canada Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 291. Canada Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 292. Canada Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 293. Canada Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 294. Canada Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 295. Canada Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 296. Canada Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 297. Canada Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 298. Canada Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 299. Canada Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 300. Mexico Drugs for HAE Market Size, 2017-2032 (USD Million)
TABLE 301. Mexico Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 302. Mexico Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 303. Mexico Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 304. Mexico Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 305. Mexico Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 306. Mexico Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 307. Mexico Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 308. Mexico Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 309. Mexico Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 310. Mexico Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 311. Mexico Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 312. Mexico Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 313. Mexico Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 314. Brazil Drugs for HAE Market Size, 2017-2032 (USD Million)
TABLE 315. Brazil Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 316. Brazil Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 317. Brazil Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 318. Brazil Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 319. Brazil Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 320. Brazil Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 321. Brazil Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 322. Brazil Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 323. Brazil Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 324. Brazil Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 325. Brazil Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 326. Brazil Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 327. Brazil Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 328. United Kingdom Drugs for HAE Market Size, 2017-2032 (USD Million)
TABLE 329. United Kingdom Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 330. United Kingdom Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 331. United Kingdom Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 332. United Kingdom Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 333. United Kingdom Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 334. United Kingdom Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 335. United Kingdom Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 336. United Kingdom Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 337. United Kingdom Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 338. United Kingdom Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 339. United Kingdom Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 340. United Kingdom Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 341. United Kingdom Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 342. Germany Drugs for HAE Market Size, 2017-2032 (USD Million)
TABLE 343. Germany Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 344. Germany Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 345. Germany Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 346. Germany Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 347. Germany Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 348. Germany Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 349. Germany Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 350. Germany Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 351. Germany Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 352. Germany Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 353. Germany Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 354. Germany Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 355. Germany Drugs for HAE Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 356. France Drugs for HAE Market Size, 2017-2032 (USD Million)
TABLE 357. France Drugs for HAE Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 358. France Drugs for HAE Market Size, by Acute Treatment, 2017-2032 (USD Million)
TABLE 359. France Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 360. France Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 361. France Drugs for HAE Market Size, by Long Term Prophylaxis, 2017-2032 (USD Million)
TABLE 362. France Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 363. France Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 364. France Drugs for HAE Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 365. France Drugs for HAE Market Size, by C1 Inhibitors, 2017-2032 (USD Million)
TABLE 366. France Drugs for HAE Market Size, by Kallikrein Inhibitors, 2017-2032 (USD Million)
TABLE 367. France Drugs for HAE Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 368. France Drugs for HAE Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 369. France Drugs for HAE Market Size, by Patient Age Group, 20

Companies Mentioned

  • ADARx Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Astria Therapeutics, Inc.
  • Attune Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • BioMarin Pharmaceutical Inc.
  • CSL Behring LLC
  • Grifols, S.A.
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Pharming Group N.V.
  • Pharvaris N.V.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Industries Ltd.

Related Topics

Related Reports

Hereditary Angioedema - Global Strategic Business Report - Product Image

Hereditary Angioedema - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Hereditary Angioedema Market Report 2026 - Product Image

Hereditary Angioedema Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Systemic Autoinflammatory Diseases Drug Market - Global Forecast 2026-2032 - Product Image

Systemic Autoinflammatory Diseases Drug Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Ulcerative Colitis Market - Global Forecast 2026-2032 - Product Image

Ulcerative Colitis Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Human Immunodeficiency Virus (HIV1) Infection Market Size - Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035) - Product Image

Human Immunodeficiency Virus (HIV1) Infection Market Size - Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

  • Report
  • 350 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.